Answers are grounded in this paper and cite their sources.
Poly(vinylpyrrolidone) (PVP)-stabilized Pt clusters (1.4 nm average particle size) were embedded in an amorphous microporous titania−silica mixed oxide (AMM- Me Si 30 Ti) by means of a modified sol−gel procedure. The Pt particles were shown by transmission electron microscopy to retain their approximate original average diameter. The catalytic activity of the Pt-colloid-containing titania−silica mixed oxide catalysts was tested with the hydrogenation of 2-hexyne at 1 bar in decane or 1-propanol in a batch reactor. Selectivities to cis / trans -2-hexene were higher than those for PVP-stabilized colloids dispersed in the liquid phase. In colloidal dispersions of the PVP-stabilized catalyst in propanol, an initial 2-hexene selectivity of 80% at a conversion of <10% fell to ca. 45% at 100% conversion. With the AMM-supported catalyst, a 2-hexene selectivity of >94% was observed at hexyne conversions up to 50%, and at complete conversion a selectivity to 2-hexenes of 88% was achieved ( cis -2-hexene selectivity of 91%). Thermal treatment of the platinum-containing AMM- Me Si 30 Ti in an oxygen atmosphere leads to the removal of the protective PVP shell surrounding the colloids inside the sol−gel material, as detected by 13 C-MAS NMR spectroscopy, resulting in an increase in both surface area and Pt particle size. The resulting catalysts showed lower selectivity for 2-hexene. A control experiment showed that the presence of PVP was responsible for the high selectivities to cis / trans -2-hexene exhibited by the AMM-supported colloidal Pt catalysts.
No takes yet. Share an insight, caveat, or question.
Lange et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: